An observational study in Ulcerative Colitis, sponsored by Ferring Pharmaceuticals. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-20.
Sponsored by Ferring Pharmaceuticals · Observational
For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for how long and how these differences impact the patient disease state and work productivity.
1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.
This study's enrollment of 150 is above the median of 105 across 247 observational studies indexed under Colitis.
Browse Colitis studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Out-patient clinics in the Netherlands
Exclusion Criteria:
Treatment according to standard clinical practice.
Drug: mesalazine
Also known as: Pentasa
Time to dose reduction
Time frame: From Day 1 up to one year
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals